Latest Merck Research Laboratories Stories
Overall Response Rate of 66 Percent Observed in Pembrolizumab-treated Patients Whose Cancer Progressed on Brentuximab Vedotin Phase 2 Study Planned for the First Half of 2015
Agreement to fund development of compounds for cognitive impairment associated with Alzheimer's disease and other conditions of the central nervous system SAN DIEGO,
CAMBRIDGE, Mass., June 2, 2014 /PRNewswire/ -- Seres Health, a clinical-stage therapeutics company developing novel products to treat a host of disease conditions based on scientific findings
WUPPERTAL, Germany and WHITEHOUSE STATION, New Jersey, May 8, 2014 /PRNewswire/ -- AiCuris and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today
- A member of the swell-mob; a genteelly clad pickpocket. Sometimes mobsman.